2025年IDF世界糖尿病大会

◆ 会议时间：2025年4月7-10日
◆ 会议地点：泰国曼谷

◆ 会议简介：

2025年国际糖尿病联合会(IDF)大会-世界糖尿病大会将2025年4月7-10日在泰国曼谷举行。IDF世界糖尿病大会是国际糠尿病联合会的一项核心活动，每两年在世界各地举办一次，从1952年在荷兰莱顿举行的第一次大会到最近在2019年在韩国釜山举行的IDF大会，与会人数已经从几百名增长到12,000余人。IDF世界大会提供了一个全球性的平台，以讨论广泛的糖尿病问题，从最新的科学进展到有关教育、糖尿病护理、宣宣传和认识方面的前沿信息等等。参与者包括医生、科学家、护士、教育工作者和其他医疗专业人士，以及政府代表、决策者、糖尿病患者、IDF成员和媒体代表等等。

国际糖尿病联合会（IDF）是一个由全球170个国家和地区的240多个糖尿病协会成员构成的伞状组织，代表着越来越多糖尿病患者和那些高危人群者的利益。自1950年以来，IDF一直是全球糖尿病界的领导者。IDF的使命是促进糖尿病的护理、预防和全球性的治疗。IDF的国家糖尿病协会分为七个区域：非洲、欧洲、中东和北非、北美和加勒比地区、南美和中美洲、东南亚和西太平洋，目的是促进各个国家糖尿病协会的工作并加强它们之间的合作。IDF每两年在世界各地举办一次世界大会。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）

International Diabetes Federation (IDF) World Diabetes Congress 2025

时间/ Dates:
April 7-10, 2025

会场/Venue:
Bangkok International Trade & Exhibition Centre
Bangkok, Thailand

组织/Organiser: International Diabetes Federation （IDF）

IDF World Diabetes Congress

Held every two years, the IDF World Diabetes Congress ranks as one of the largest global medical meetings covering all facets of diabetes. Participants from across the globe meet to learn about a broad range of diabetes issues, from the latest scientific advances to cutting-edge information on education, diabetes care, advocacy and awareness.

From the first congress held in Leiden, the Netherlands, in 1952 to the most recent one in Lisbon in 2022, the number of participants has grown from a few hundred to over 12,000 delegates from 180 countries.

摘要征文投稿：

Abstract submission: 15 July – 15 September 2024

点此提交摘要>>>Submit Abstract>>>

The IDF World Diabetes Congress 2025 welcomes original abstracts on subjects relevant to the following streams:

Basic and Translational Science (BTS)
Classification and Differential Management of Diabetes (CDM)
Technology and Artificial Intelligence (TAI)
Diabetes Complications (DC)
Type 1 Diabetes (T1D)
Public Health and Policy (PHP)
Education and Integrated Care (EIC)
Epidemiology and Prevention of Diabetes (EPD)
Women and Diabetes (WAD)
Living with Diabetes (LWD)

Submission guidelines

Submission mode: Abstract submission is only possible online. Abstracts submitted by post, fax or email will NOT be accepted. The online abstract submission module will NOT be available after 15 September 2024.

IDF congress profile: In order to submit an abstract, a congress profile must be created giving access to the online abstract submission module. The submitting author must ensure accurate contact details are entered. One or more abstracts can be submitted by logging into this congress profile.

Submitting and presenting author: If the submitting author is not also the presenting author, the submitting author is responsible for informing the presenting author of all communications received regarding the abstract.

Presenting author registration: The presenting author must be registered by 31 December 2024. If the presenting author is not registered by this date their abstract will be REMOVED from the programme. To benefit from the early registration rate, the presenting author must register by 31 October 2024. After this date the standard rate will apply.

Number of submissions: There can only be ONE presenting author per abstract. The same abstract CANNOT be submitted multiple times by listing different presenting authors. An unlimited number of abstracts can be submitted by one author.

Language: All abstracts must be submitted in English. Should English not be your first language, you may wish to have your abstract examined by a native English speaker prior to submission.

ENCORE abstracts/Originality of abstracts: Work published in peer-reviewed journals before 7 April 2025 CANNOT be submitted to the IDF World Diabetes Congress 2025. Abstracts already presented at face-to-face meetings can also NOT be submitted. However, previously submitted work can be resubmitted provided there are new methods and/or findings. Abstracts already presented at a national virtual meeting can be resubmitted. However, previously submitted work CANNOT be resubmitted, if it was presented at an international virtual meeting.

Disclosure of interests: Any financial relationships with commercial entities related to the authors or products and processes described in the work must be correctly disclosed.

Regulatory approval: The submitting author confirms that local regulatory approval has been obtained as required by local laws.

Author consent: The submitting author declares all authors have read and approved the submitted work.

Copyright transfer: Authors must attest that their submitted work does not infringe any copyright legislation. Copyright for the publication of abstracts is automatically transferred to the International Diabetes Federation upon submission and acceptance of the regulations within the online submission module. For rejected abstracts, the copyright reverts back to the authors.

Publication in DRCP: Best abstracts will be published online in the IDF official journal Diabetes Research and Clinical Practice (DRCP). The approximate publication date is Sep/Oct 2025. Accepted abstracts will be published as submitted through the IDF 2025 Abstract Submission Portal. Any changes made to the digital poster submission will not be reflected in DRCP. Abstracts cannot be removed or corrected once they are published in DRCP.

Submission instructions

Topic: There are various categories that have been defined for the abstract programme within the ten streams. Ensure that you select the MOST relevant stream that BEST reflects the content of your abstract. Categories are used for reviewing and indexing purposes.

Abstract title: The title is limited to 120 characters including spaces and should be brief and relevant. Special characters can NOT be used in the title and should be spelt out instead (e.g. α needs to be written as alpha, β as beta). Only standard abbreviations and generic drug names are allowed in the title.

Authors: Only 12 authors and/or study groups can be listed. Only one institution can be entered per author.

Abstract body:

The abstract structure is laid out under the headings: Background, Aim, Method, Results, Conclusion and References.
Font size and style will be automatically configured by the system.
Tables Maximum of 1 Table OR 1 Figure will be accepted in the submission field and count towards the character limit. Figures or Tables included in an abstract need to have a mention of this in the abstract text (e.g. Table or Figure 1). The character deduction for tables is not fixed and will be generated by the character count shown below the submission field. The table/figure must not contain more than 480 characters. The table must have a maximum of 10 columns and 12 rows. Figures must have a maximum of two panels. Images and photographs are NOT allowed.
The length of the abstract is limited to 2100 characters with spaces. Only the abstract body and any inserted tables count towards this character limit. The character count displayed beneath the submission field is final and indisputable.
Only commonly accepted abbreviations should be used (e.g. GDM, BMI, DM). Treatment groups or drug names should NOT be abbreviated. Less widely recognised abbreviations may be used if introduced on first usage (e.g. ambulatory blood pressure monitoring, ABPM).
Only approved and generic (non-proprietary) drug names should be used.
Do NOT enter the title, authors, or grant information into the abstract body, but you can include up to three references at the end of the abstract. References need to be numbered (reference number in square brackets) and must have a matching citation number (citation number in square brackets).

Selection and notification process

Selection: All submitted abstracts will undergo review by the Programme Committee. Accepted abstracts are selected for oral presentation, poster presentation or e-poster gallery display. The Programme Committee reserves the right to accept or reject any submitted abstract and re-categorise any accepted abstract. The decision of the Programme Committee is final and irrevocable.

Notification: Notice of acceptance or rejection of submitted abstracts will be sent to the submitting authors by 25 October 2024. It is the responsibility of the submitting author to inform all other authors of the status of the abstract. A submitting author may also check their congress profile to see the status of their abstract.

注册费：

The registration fee includes

Access to all sessions
Access to all abstracts and posters through the e-poster gallery onsite and online
Access to all industry sponsored symposia
Access to all recorded sessions – View on Demand – for 30 days after the event
Access to the exhibition onsite
Access to opening and closing ceremonies
CME certification for onsite attendance
Congress material
Personalized Invitation letter
Access to the IDF 2025 Congress App

2025年IDF世界糖尿病大会